First Human Trial of Oxford Coronavirus Vaccine Shows It’s Safe


Scientists at Oxford University said that the early trial of their experimental coronavirus vaccine, called AZD1222, prompted a protective immune response in hundreds of people who got the shot.


According to trial results published in The Lancet medical journal on Monday, AZD1222 being developed by AstraZeneca and scientists at the United Kingdom’s University of Oxford, did not prompt any serious side effects and elicited antibody and T-cell immune responses.


According to the research, the scientists found their experimental Coronavirus vaccine produced a dual immune response in people aged 18 to 55 that lasted at least two months after they were immunised.


Dr Adrian Hill, director of the Jenner Institute at Oxford University, said:

“We are seeing good immune response in almost everybody. What this vaccine does particularly well is trigger both arms of the immune system.”


Dr Hill added that larger trials evaluating the vaccine’s effectiveness, which would involve about 10,000 people in the UK as well as participants in South Africa and Brazil are still under way. Also, another big trial is slated to start in the US soon, aiming to enrol about 30,000 people.

Comments are closed.